Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination. - Suppr | 超能文献

Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination.

作者信息

Yasukawa M, Ochi T, Fujiwara H

机构信息

Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan.

Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan.

出版信息

Ann Oncol. 2010 Oct;21(10):2122-2124. doi: 10.1093/annonc/mdq544.

DOI:10.1093/annonc/mdq544

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination.

Ann Oncol. 2010 Oct;21(10):2122-2124. doi: 10.1093/annonc/mdq544.

2

Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.在用人端粒酶逆转录酶（hTERT，I类和II类）肽脉冲树突状细胞（DCs）进行疫苗接种期间，体内肽特异性细胞毒性T细胞的产生及调节性T细胞的存在。

J Transl Med. 2009 Mar 19;7:18. doi: 10.1186/1479-5876-7-18.

3

Immunization with short peptide particles reveals a functional CD8 T-cell neoepitope in a murine renal carcinoma model.免疫短肽颗粒揭示了一种功能性 CD8 T 细胞新表位在小鼠肾细胞癌模型中的作用。

J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003101.

4

A vaccine in renal cell carcinoma: are we nearing reality?肾细胞癌疫苗：我们正在接近现实吗？

Expert Rev Anticancer Ther. 2012 Dec;12(12):1503-5. doi: 10.1586/era.12.139.

5

Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24 patients with renal cell carcinoma.能够从患有肾细胞癌的HLA - A24患者中诱导产生癌症反应性细胞毒性T淋巴细胞的缺氧诱导因子（HIF）-1α衍生肽。

Int Immunopharmacol. 2017 Mar;44:197-202. doi: 10.1016/j.intimp.2017.01.014. Epub 2017 Jan 19.

6

Tailor-made renal cell carcinoma vaccines.定制的肾细胞癌疫苗。

Cancer Cell. 2012 Sep 11;22(3):287-9. doi: 10.1016/j.ccr.2012.08.021.

7

WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.WT1（肾母细胞瘤1）肽免疫疗法治疗肾细胞癌。

Microbiol Immunol. 2007;51(5):519-30. doi: 10.1111/j.1348-0421.2007.tb03940.x.

8

Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.在转移性肾细胞癌患者中有效诱导识别源自缺氧诱导蛋白2（HIG2）的表位肽的细胞毒性T细胞。

Cancer Immunol Immunother. 2017 Jan;66(1):17-24. doi: 10.1007/s00262-016-1915-5. Epub 2016 Oct 18.

9

Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.端粒酶（hTERT 611 - 626）在B细胞慢性淋巴细胞白血病中作为肿瘤抗原，并自发产生抗白血病的细胞毒性T细胞。

Exp Hematol. 2007 Feb;35(2):297-304. doi: 10.1016/j.exphem.2006.10.006.

10

Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.与肿瘤细胞融合的同种异体树突状细胞：转移性肾细胞癌患者的临床前结果及I/II期临床试验结果

Hum Gene Ther. 2003 Mar 20;14(5):483-94. doi: 10.1089/104303403321467243.

引用本文的文献

1

hTERT promotes gastric intestinal metaplasia by upregulating CDX2 via NF-κB signaling pathway.人端粒酶逆转录酶通过核因子κB信号通路上调CDX2，从而促进胃黏膜肠化生。

Oncotarget. 2017 Apr 18;8(16):26969-26978. doi: 10.18632/oncotarget.15926.